$17.11
3.01% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US1523091007
Symbol
CNTA

Centessa Pharmaceuticals plc - ADR Stock price

$17.11
+1.98 13.09% 1M
-0.89 4.94% 6M
+0.36 2.15% YTD
+6.56 62.18% 1Y
+12.85 301.64% 3Y
-4.64 21.33% 5Y
-4.64 21.33% 10Y
-4.64 21.33% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.50 3.01%
ISIN
US1523091007
Symbol
CNTA
Industry

Key metrics

Basic
Market capitalization
$2.3b
Enterprise Value
$2.1b
Net debt
positive
Cash
$284.5m
Shares outstanding
133.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
151.5 | 162.1
EV/Sales
139.9 | 149.6
EV/FCF
negative
P/B
5.9
Financial Health
Equity Ratio
69.6%
Return on Equity
-58.7%
ROCE
-45.6%
ROIC
-98.8%
Debt/Equity
0.3
Financials (TTM | estimate)
Revenue
$15.0m | $14.0m
EBITDA
$-228.9m | $-193.9m
EBIT
$-229.8m | $-188.4m
Net Income
$-223.9m | $-177.4m
Free Cash Flow
$-162.0m
Growth (TTM | estimate)
Revenue
119.0% | -
EBITDA
-45.3% | 3.1%
EBIT
-45.0% | 6.3%
Net Income
-61.7% | 24.8%
Free Cash Flow
-8.1%
Margin (TTM | estimate)
Gross
-
EBITDA
-1,526.1% | -1,382.6%
EBIT
-1,532.3%
Net
-1,492.3% | -1,264.6%
Free Cash Flow
-1,080.1%
More
EPS
$-1.7
FCF per Share
$-1.2
Short interest
3.2%
Employees
72
Rev per Employee
$0.0
Show more

Is Centessa Pharmaceuticals plc - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Centessa Pharmaceuticals plc - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Centessa Pharmaceuticals plc - ADR forecast:

18x Buy
95%
1x Hold
5%

Analyst Opinions

19 Analysts have issued a Centessa Pharmaceuticals plc - ADR forecast:

Buy
95%
Hold
5%

Financial data from Centessa Pharmaceuticals plc - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
15 15
119% 119%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 50 50
3% 3%
331%
- Research and Development Expense 161 161
41% 41%
1,074%
-229 -229
45% 45%
-1,526%
- Depreciation and Amortization 0.92 0.92
4% 4%
6%
EBIT (Operating Income) EBIT -230 -230
45% 45%
-1,532%
Net Profit -224 -224
62% 62%
-1,492%

In millions USD.

Don't miss a Thing! We will send you all news about Centessa Pharmaceuticals plc - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Centessa Pharmaceuticals plc - ADR Stock News

Neutral
GlobeNewsWire
about 12 hours ago
Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year
Neutral
GlobeNewsWire
about one month ago
Tokyo, Japan and Cambridge, UK, 4 July 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals pursuant to its research collaboration with Centessa. The milestones were achieved as Centessa initiated clinical development of ORX142, its second novel orexin receptor 2 (OX2R) agonist,...
Neutral
GlobeNewsWire
about 2 months ago
BOSTON and LONDON, June 16, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND to initiate a Phase 1 clinical study of ORX142 in healthy volunteers. ORX142 is an investigational, novel, highly potent and selective OX2R agonist being developed for the t...
More Centessa Pharmaceuticals plc - ADR News

Company Profile

Centessa Pharmaceuticals Ltd. operates as pharmaceutical company that develops medicines. The company was founded on October 26, 2020 and is headquartered in Cambridge, the United Kingdom.

Head office United Kingdom
CEO Saurabh Saha
Employees 72
Founded 2013
Website www.centessa.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today